CompletedPhase 4

The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

Pakistan200 participantsStarted 2022-12-01

Plain-language summary

The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .

Who can participate

Age range40 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Diabetic men and women of age 40-70 yrs. * HBA1C -(6.5-9 )percent * All diabetic patients were BMI ≥25kg/m2 * Patient took metformin ≥1000mg/day for ≥ 3 months with uncontrolled DM Exclusion Criteria: * Male and female type 1 diabetic patients with BMI \<25 * Diabetic patient taking oral medicine other than metformin for last 12 weeks * Subjects with creatinine \>1.5mg/dl * Pregnant or Lactating Women * Co-morbidities - * CLD * Cancer patient

What they're measuring

Overall improvement in Fasting Blood Glucose

Timeframe: 12 weeks

Overall change in Body Mass Index ( kg/m2)

Timeframe: 12 weeks

Overall improvement in Random Blood Glucose

Timeframe: 12 weeks

Over all improvement in Glycated Hemoglobin ( HbA1c)

Timeframe: 12 weeks

Overall change in Waist to Hip Ratio

Timeframe: 12 weeks

Overall change in Waist Circumference

Timeframe: 12 weeks

Trial details

NCT IDNCT07247656

SponsorBahria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-01

View on ClinicalTrials.gov More Diabete Mellitus trials